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IT was early recognized that only a minority of women with breast cancer
are sensitive to any method of hormonal control. The proportion varies between
30 and 50 per cent according to age group and whether oestrogen or androgen is
administered (Stoll, 1950).
It was therefore noteworthy when Loeser (1954) suggested that thyroid ad-
ministration may protect against recurrence of breast cancer and that the com-
bination of male hormone with thyroid extract yielded greater clinical benefit
than the male hormone alone in mammary carcinoma. This suggestion was not
followed up by others until Bacigalupo (1959) and Luehrs (1959, 1960a) and
Luehrs and Bacigalupo (1960) reported onthe administration of 120 microgrammes
daily of tri-iodothyronine (T3) with androgen (Durabolin). They claimed that it
led to regression of growth in advanced mammary carcinoma after the androgen
alone failed to give a response. More recently Luehrs (1961a, 1961b) further
reported that mammary carcinoma which had become unresponsive to oestrogen
therapy began to respond again after administration of tri-iodothyronine.
This paper reports an attempt to confirm this latter observation in a group
of 12 patients with advanced breast cancer.
CLINICAL REPORT
A group of 12 patients with measurable soft tissue lesions of advanced breast
carcinoma beyond control by X-ray therapy, were given 15 mg. stilboestrol daily.
In 4 ofthe patients who developed severe vomiting on stilboestrol, 15 mg. Premarin
(natural conjugated oestrogens) was substituted with no observable intolerance.
All patients were more than 1 year postmenopausal with an atrophic vaginal
smear. Patients selected for therapy had to show unmistakable objective signs
of advancing disease and measurable soft tissue lesions of advanced breast carci-
noma capable of being followed by photograph or X-ray. Patients with a history
of angina pectoris, coronary artery disease or clinical thyroid disease were ex-
eluded. None of the group received concomitant X-rav or chemotherapy at the
time of the clinical trial or within the preceding month.
In 10 of the cases, thyroid extract was added, rising to 600 mg. daily, if no
signs of intolerance appeared. In 5 of these, the patient was transferred after
about 2 months to tri-iodothyronine, rising to 200 ,ig. daily. In 2 of the 12 cases,
T3was given from the start oftherapy.
Treatment was continued for 3 months or longer except in 3 cases where it
was stopped at 2 months because of severe side effects or because of undoubtedTRI-IODOTHYRONINE AS A HORMONE POTENTIATOR
progression of the disease. Apart from routine clinical examination, investigation
and photographs, the following special investigations were carried out:
(1) Initial 2- and 24-hour thyroid uptake of 131i, checked in cases of low
uptake by the thyrotropic hormone stimulation test (Jefferies et al.,
1953)
(2) Vaginal smear at 2-weekly intervals with especial reference to the
degree of cornification as shown by the Karyo-Pyknotic Index (K.P.I.);
(3) Serum cholesterol investigations at 2-weekly intervals.
rl'achycardia, excitability, headaches and sweating were only rarely com-
plained of by the patients under treatment. In only 2 cases did the pulse rate
rise at any time above 108 per minute. However, excessive tiredness was com-
plained ofin 3 cases and generalised aching in 2 cases, relieved when T3 or thyroid
extract administration was ceased. In 3 cases treatment had to be stopped because
of serious weight loss and in 1 case because of right heart failure.
RESULTS OF THERAPY
1. In 3 of the 12 cases there was response of soft tissue growth which could
be demonstrated in photographs. These comprise 2 of 8 stilboestrol treated cases
and 1 of 4 Premarin treated cases (Table I).
TABLE I.-Clinical Results of Oestrogen Administration and Added T3 or
Thyroid Extract
Previous
hormone
Patient Age response
M.C. 70 Stil.
Reg. 4/12
B.M. . 54 Halo 6/12
No change
R.. 79 . Eth. Oest.
Reg. 12/12
E.G. . 49 Halo.
Reg. 28/12
A.V. 65 . -
L.S. 67 Stil.
Reg. 261/12
H.M. 61 Halo.
Reg. 8/12
Z.C. . 69
M.T. 56
T.B. 45
CC. 70
N.P. . 65
Reg. = Regression.
Oestrogen
and
duration
Stil. 5/12
Prem. 5/12
Prem. 3/12
Stil. 3/12
Th. = Ext. Thyroid.
T.3 = Tri-Jodo-Thyronine
Daily dose and duration
.Th. 200-600 mg.
T.3 120-200 ,pg.
.Th. 200-600 mg.
T.3 120-200 ,ug.
.Th. 200-600 mg.
T.3 120 lig.
.Th. 200-400 iiig.
T.3 120-160,g.
Effect on soft
tissue lesion
2/12 No change.
3/12
2/12 . Reg.
3/12
2/12 . No change.
1/12
1/12 . Progression.
2/12
Stil. 5/12 . T.3 120-200 3/12 alone . Progression <
T.3 200 5/12 with Stil. Reg. when S
Stil. 4/12 . Th. 200-600 mg. 3/12 . Progression.
T.3 120-160 pg. 1/12
Prein. 5/12 . T.3 60-200 yg. 5/12 . No change.
Stil. 2/12 . Thi. 100-300 mg.
Stil. 4/12 . Th. 200-600 mg.
Stil. 2/12
Stil. 2/12
Prem. 2/12
Th. 200-300 mg.
Th. 200-600 mg.
Th. 200 mg.
Key:
Halo. = Halotestin. Stil = Stilboestrol
15 mg. daily.
Eth Oest.= Ethinyl Oestradiol
3 mg. daily.
On T.3.
stil. added.
2/12 . No change.
4/12 . Reg. but new bone met-
astases.
2/12 . No change.
2/12 . Progression.
2/12 . No change.
Premn. = Premarin
15 mg. daily.
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2. Of 3 cases who had previously shown good response to oestrogens and be-
come resistant, not one showed any further response by the addition of T3 to
oestrogen therapy (Luehrs, 1961a and b).
3. One patient (A. W.), showing active progression of disease after 3 months
on T3 alone, showed good regression on adding oestrogens.
4. Of the responding cases 1 received thyroid extract, 1 received T3 and the
third received the two in succession. The dose of thyroid or T3 used in the trial
was sufficient to cause an average fall ofabout 33 per cent in the serum cholesterol
levels of the series, and to necessitate stopping the drug in 3 cases because of
severe side effects (Table II).
TABLE II.J 1311 Uptake of Cases Before Therapy in Relation to Side Effects
of Therapy
Patient Age
M.C. . 70 .
131i
uptake
2
2hr. 24hr.
15 41
Th. = Ext. thyroid.
T.3 = Tri-iodothyronine
Daily dose and duration
. Th. 200-600 mg. 2/12
T.3 120-200 psg. 3/12
B.M. . 54 . 20 46 . Th. 200-600 mg. 2/12
T.3 120-200 jug. 3/12
R.R. . 79 . 13 42 . Th. 200-600 mg. 2/12
T.3 120 pug. 1/12
E.G. . 49 . 5 6 . Th. 200-400 mg. 1/12
T.3 120-160 MAg. 2/12
Serum
cholesterol
Onset End
. 208 135 .
. 264 138 .
Max.
Side pulse
effects rate
- 96
Vaginal
K.P.I.
At
1/12 End
. 54 20
- . 108 . 62 36
244 140 . Loss weight .
+tiredness
. 130 103 .
108 . 64 64
- . 108 . 20 14
A.W. . 65 . 36
L.S. . 67 . 8
H.M. . 61 . 13
Z.C. . 69 . 9
M.T. . 56 . 20
70 . T.3 120-200 3/12 alone
T.3 200 5/12 with Stil.
12 . Th. 200-600 mg. 3/12
T.3 120-160 pg. 1/12
. 269 139 .
. 204 180 .
39 . T.3 60-200 mg. 5/12 . 265 137
32 . Th. 100-300 mg. 2/12 . 314 230 .
51 . Th. 200-600 mg. 4/12 . 230 142
. 120 . 60 91
. 108 . Tricho-
monas
Tiredness,
aching
R. heart
failure
Loss weight .
+tiredness
108 . 48 11
96 . 26 63
96 . 52 63
T.B. . 45 . 9 42 . Th. 200-300 mg. 2/12 226 180 . Loss weight . 114 . 28 46
+tiredness
C.C. . 70 . 17
N.P. . 65 . 17
36 . Th. 200-600 mg. 2/12 . 275 217 .
47 . Th. 200 mg. 2/12 . 283 209 .
- . 96 . 21 20
Tiredness,
aching
78 . 15 19
5. The mean level of the K.P.I. of the vaginal smears after 1 month on com-
bined therapy (41 per cent) is of the same level as that seen in 30 cases treated by
the author using oestrogen alone (43 per cent). There is no suggestion that the
initial level of cornification is maintained for any longer period. There is thus
no evidence that thyroid or T3 administration increases the vaginal sensitivity
to oestrogen at the dose specified.
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DISCUSSION
Several recent papers have investigated a possible relationship between the
incidence of breast cancer and decreased activity of the thyroid gland (Loeser,
1954; Sommers, 1955; Ellerker, 1956; Rawson, 1956; Edelstyn, Lyons and
Welbourn, 1958; Marques, Bru and Espinosse, 1959; Hortling, Hilsi-Brummer
and Bjorresten, 1959; Finley and Bogardus, 1960; Carter and Feldman, 1960;
Reeve et al., 1961 ; Sicher and Waterhouse, 1961). The relationship has been
investigated by demographic, biochemical and experimental approaches. From
the investigation of 150 breast cancer patients the present author concluded that
there was no statistically valid evidence that hypothyroidism was associated with
an increased predisposition to breast cancer. However, the presence of activelv
growing breast cancer seems to be associated with depression of thyroid uptake of
radioactive iodine under specific circumstances.
This present report seems to lend confirmation to the previous finding, in that
two patients (E.G. and L.S.) showed surprisingly low 24-hour 131J uptakes (6 and
12 respectively) not increased by TSH stimulation. Although according to
Loeser (1954) one might have expected these to benefit from thyroid or T3 ad-
ministration, yet they showed no regression of tumour on combined therapy.
SUMMARY
It has been suggested that thyroid administration is protective against re-
currence of breast cancer and that a tumour which has lost response to hormone
therapy may respond again if thyroid extract or T3 is added.
A series of 12 cases of advanced breast carcinoma were treated by a combina-
tion of oestrogen and tri-iodothyronine (or thyroid extract). The proportion of
regression seen in this series is that which would be expected from oestrogen
administration alone. In spite ofother reports in the literature there is no evidence
that the administration of thyroid or T3 at the dose given:
(a) causes regression of mammary carcinoma when given alone;
(b) shows any synergism with oestrogens in the treatment of mammaryr
carcinoma;
(c) in combination with oestrogens leads to a response in mammary carci-
noma which has become resistant to oestrogen therapy.
The author has shown that some patients with actively growing breast cancer
show depression of thyroid uptake of radioactive iodine. Two patients in this
series with grossly low levels showed no regression oftumours on combined oestro-
gen, thyroid (or T3) therapy.
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